Wegovy medication type explained: what class of drug is it?

You've heard of GLP-1s, here's what that actually means for Wegovy

Picture the last time you finished a satisfying meal and felt genuinely full. Part of that feeling comes from a hormone called GLP-1 (glucagon-like peptide-1), released in your gut when you eat. It travels to your brain, slows the rate at which your stomach empties, and tells your appetite centres to ease off. Semaglutide, the molecule in Wegovy, is a synthetic version of that signal, engineered to last far longer in the body than the natural hormone, which breaks down within minutes.

That extended action is why Wegovy is injected once a week rather than daily. The drug binds to GLP-1 receptors in the brain, gut and pancreas, reducing appetite, slowing gastric emptying and helping regulate blood glucose. You can read more about semaglutide's broader pharmacology on the semaglutide medication class page, which covers the receptor biology in more detail.

This puts Wegovy in the same drug class as several other medicines, but not all of them are licensed for weight loss. Understanding the class helps you avoid a common and sometimes costly confusion, which the next section addresses directly.

Wegovy, Ozempic, Rybelsus: same molecule, very different licences

Semaglutide exists under three brand names in the UK, and the differences matter legally and clinically. Wegovy medication in its injected form is licensed for weight management, and our dedicated page explains exactly what that licence covers. The different semaglutide medication names page maps this out fully, but the short version is this: Ozempic, also an injection, is licensed for type 2 diabetes (not weight loss) and the MHRA is clear on that distinction. Rybelsus is an oral tablet of semaglutide licensed for type 2 diabetes; again, not for weight management.

In June 2026 the MHRA approved Wegovy tablets (oral semaglutide, 25mg maintenance dose) as the first oral GLP-1 medicine licensed in the UK specifically for weight management, a separate product from Rybelsus, with its own dosing schedule and licence. For anyone researching the medication by name, it is worth being precise: Wegovy's medication name and licence cover a specific indication, and switching between products without clinical input is not appropriate.

The MHRA has also been clear that Ozempic should not be used off-label for weight loss; prescribing it that way falls outside its licence and has contributed to supply pressures affecting people with diabetes who rely on it.

How Wegovy sits alongside tirzepatide, the other injectable in UK weight management

Wegovy is not the only injectable GLP-1-class medicine licensed for weight management in the UK. Mounjaro (tirzepatide) activates two receptors (GLP-1 and GIP) making it a dual agonist, whereas semaglutide targets GLP-1 alone. That single difference in mechanism is part of why the trial results differ between the two. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks.

Both remain prescription-only medicines requiring clinical assessment. Which suits a particular person depends on their medical history, current medicines and how they respond to treatment, not on a headline trial figure. The weight-loss treatment overview sets out how these options compare in practical terms, and our prescribers work through exactly this kind of question during a consultation. Cost context for Wegovy and Mounjaro, including what a legitimate private prescription typically includes, is covered on our Wegovy information page.

Worth knowing: the MHRA approved a dedicated 7.2mg single-dose Wegovy pen in April 2026, with trial data showing around 20.7% average weight loss over 72 weeks at that dose, narrowing the gap with tirzepatide's highest-dose results. Specific dose availability is always confirmed at consultation rather than assumed.

What being a prescription-only medicine means in practice

Because Wegovy is a POM, the only legal route to it in the UK is a prescription issued after a clinical assessment. That assessment looks at your BMI, your medical history, any other medicines you take (oral contraceptives need particular attention with semaglutide; the NHS England guidance on weight management injections covers this), and whether any conditions make these medicines unsuitable. If you are also prescribed stimulants or other treatments for attention deficit hyperactivity disorder, it is worth reading about semaglutide and ADHD medication together, as there are interactions your prescriber will want to consider.

The NHS medicines page for semaglutide on the NHS website lists the main side effects and contraindications clearly. The most common are gastrointestinal (nausea, loose stools, indigestion) typically most noticeable in the first few weeks or after a dose increase, and settling for most people as the body adjusts.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it's submitted. If treatment is clinically approved, it's dispatched the same day and arrives via DPD the next working day in plain, unmarked packaging, the pen itself is small, discreet and comes in a pre-filled format. If you'd like to check whether Wegovy may be appropriate for your situation, check your eligibility through a free consultation with our clinical team.